SKYE - Skye Bioscience, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
1.52 0.01 (0.66%)	---	0.0 (0.0%)	-0.01 (-0.64%)	0.03 (1.97%)	0.0 (0.32%)	-0.03 (-1.92%)	-0.03 (-1.92%)

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.44
Diluted EPS:: -0.44
Basic P/E:: -3.4773
Diluted P/E:: -3.4773
RSI(14) 1m:: 0.0
VWAP:: 1.53
RVol:: 0.2825

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	1.57 +0.02 (+1.39%)	Oct 15 14:02
1m	Price increase 1m	1.58 +0.02 (+1.28%)	Oct 15 12:16
1m	Price decrease 1m	1.54 -0.04 (-2.53%)	Oct 15 09:51
1m	Price decrease 1m	1.56 -0.02 (-1.27%)	Oct 15 08:59
1m	Price increase 1m	1.6 +0.03 (+1.89%)	Oct 15 08:05